A reassessment of the role of B7-1 expression in tumor r

Journal of Experimental Medicine

182, 1415-1421

DOI: 10.1084/jem.182.5.1415

#	Article	IF	Citations
1	Triggering of Natural Killer Cells by the Costimulatory Molecule CD80 (B7-1). Immunity, 1996, 5, 311-317.	6.6	220
2	Induction of Antigen-Specific Tumor Immunity by Genetic and Cellular Vaccines against MAGE: Enhanced Tumor Protection by Coexpression of Granulocyte-Macrophage Colony-Stimulating Factor and B7-1. Molecular Medicine, 1996, 2, 545-555.	1.9	54
3	Genetic approaches to cancer immunotherapy. , 1996, 129, 1-49.		14
4	Granulocyte-macrophage colony-stimulating factor and the immune system. Medical Oncology, 1996, 13, 133-140.	1.2	55
5	Costimulation by CD28 sFv expressed on the tumor cell surface or as a soluble bispecific molecule targeted to the L6 carcinoma antigen. Tissue Antigens, 1996, 48, 242-254.	1.0	19
6	Differential modulation of B7-1 and B7-2 isoform expression on human monocytes by cytokines which influence the development of T helper cell phenotype. European Journal of Immunology, 1996, 26, 1273-1277.	1.6	114
7	Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. European Journal of Immunology, 1996, 26, 1335-1341.	1.6	135
8	Antigen-specific targeting of CD28-mediated T cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors. European Journal of Immunology, 1996, 26, 2304-2309.	1.6	115
9	Immunotherapy II: Antigens, receptors and costimulation. Cancer and Metastasis Reviews, 1996, 15, 329-349.	2.7	8
10	Surface Expression of CD28 Single Chain Fv for Costimulation by Tumor Cells. Immunological Reviews, 1996, 153, 209-223.	2.8	18
11	Expression of Co-Stimulatory Molecules by Tumor Cells Decreases Tumorigenicity but May Also Reduce Systemic Antitumor Immunity. Human Gene Therapy, 1996, 7, 1771-1779.	1.4	34
12	Antitumor Responses Induced by Transgenic Expression of CD40 Ligand. Human Gene Therapy, 1997, 8, 1935-1943.	1.4	64
13	Enhanced Immunogenicity of B Cell Lymphoma Genetically Engineered to Express Both B7-1 and Interleukin-12. Human Gene Therapy, 1997, 8, 2217-2228.	1.4	29
14	Effect of Canarypox Virus (ALVAC)-Mediated Cytokine Expression on Murine Prostate Tumor Growth. Journal of the National Cancer Institute, 1997, 89, 428-436.	3.0	67
15	Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 10889-10894.	3.3	141
16	Granulocyte-Macrophage Colony-Stimulating Factor and B7-2 Combination Immunogene Therapy in an Allogeneic Hu-PBL-SCID/Beige Mouseâ€"Human Glioblastoma Multiforme Model. Human Gene Therapy, 1997, 8, 1073-1085.	1.4	66
17	Irradiated NC Adenocarcinoma Cells Transduced with Both B7.1 and Interleukin-2 Induce CD4+-Mediated Rejection of Established Tumors. Human Gene Therapy, 1997, 8, 477-488.	1.4	33
18	Costimulation, tolerance and ignorance of cytolytic T lymphocytes in immune responses to tumor antigens. Life Sciences, 1997, 60, 2035-2041.	2.0	41

#	Article	IF	Citations
19	The Promise and Reality of Cancer Gene Therapy. American Journal of Human Genetics, 1997, 61, 785-789.	2.6	23
20	Immunological Gene Therapy Approaches for Malignant Melanoma. Skin Pharmacology and Physiology, 1997, 10, 105-125.	1.1	12
21	Gene transfer of costimulatory molecules B7â€“1 and B7â€“2 into human multiple myeloma cells by recombinant adeno-associated virus enhances the cytolytic T cell response. Gene Therapy, 1997, 4, 726-735.	2.3	45
22	Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes. Nature Biotechnology, 1997, 15, 641-646.	9.4	209
23	Molecular cancer vaccines: Tumor therapy using antigen-specific immunizations. Pathology and Oncology Research, 1997, 3, 164-176.	0.9	1
24	Targeting an anti-viral CD8 + T cell response to a growing tumor facilitates its rejection. Cancer Immunology, Immunotherapy, 1997, 44, 230-238.	2.0	17
25	Lack of correlation between rejection of tumor cells co-expressing interleukin-2 and B7.1 and vaccine efficiency. European Journal of Immunology, 1997, 27, 1657-1662.	1.6	16
26	Vaccination as immunotherapy for B cell lymphoma. , 1997, 15, 129-139.		9
27	GM-CSF and B7-1 (CD80) co-stimulatory signals co-operate in the induction of effective anti-tumor immunity in syngeneic mice. , 1997, 73, 556-561.		24
28	Tumour cell expression of B7 costimulatory molecules and interleukin-12 or granulocyteâ€“macrophage colony-stimulating factor induces a local antitumour response and may generate systemic protective immunity. Gene Therapy, 1998, 5, 223-232.	2.3	63
29	Vaccine effect of granulocyteâ€“macrophage colony-stimulating factor or CD80 gene-transduced murine hematopoietic tumor cells and their cooperative enhancement of antitumor immunity. Gene Therapy, 1998, 5, 1355-1362.	2.3	37
30	Comparison of four strategies for tumour vaccination in the B16-F10 melanoma model. Gene Therapy, 1998, 5, 1447-1454.	2.3	25
31	Expression of B7 co-stimulatory molecules by B16 melanoma results in a natural killer cell-dependent local anti-tumour response, but induces T-cell-dependent systemic immunity only against B7-expressing tumours. British Journal of Cancer, 1998, 78, 1043-1050.	2.9	15
32	Enhancement of the anti-tumor immune response using a combination of interferon-Î³ and B7 expression in an experimental mammary carcinoma. , 1998, 77, 107-113.		47
33	Absence of B7.1-CD28/CTLA-4-mediated co-stimulation in human NK cells. European Journal of Immunology, 1998, 28, 780-786.	1.6	58
34	The threshold for autoimmune T cell killing is influenced by B7-1. European Journal of Immunology, 1998, 28, 949-960.	1.6	40
35	Adenoviral transduction of melanoma cells with B7-1: antitumor immunity and immunosuppressive factors. Cancer Immunology, Immunotherapy, 1998, 46, 283-292.	2.0	19
36	NK CELL RECEPTORS. Annual Review of Immunology, 1998, 16, 359-393.	9.5	1,553

#	Article	IF	Citations
37	GENE THERAPY FOR MELANOMA IN HUMANS. Hematology/Oncology Clinics of North America, 1998, 12, 519-538.	0.9	9
38	The role of B7-CD28 co-stimulation in tumor rejection. International Immunology, 1998, 10, 791-797.	1.8	28
39	Cancer vaccine development. Expert Opinion on Investigational Drugs, 1998, 7, 1439-1452.	1.9	2
40	Co-expression of B7â€"1 with Interleukin-12 Enhances Vaccine-induced Antitumour Immunity in Experimental Myeloma. Hematology, 1998, 3, 365-374.	0.7	2
41	CD40 and CD70 Co-Stimulate a Potent In Vivo Antitumor T Cell Response. Journal of Immunotherapy, 1998, 21, 225.	1.2	44
42	Interleukin-12â€"Activated Natural Killer Cells Recognize B7 Costimulatory Molecules on Tumor Cells and Autologous Dendritic Cells. Blood, 1998, 91, 196-206.	0.6	75
43	Progress in Cancer Gene Therapy. Acta OncolÃ³gica, 1999, 38, 675-683.	0.8	35
44	The role of herpes simplex virus thymidine kinase in the treatment of solid tumours. Expert Opinion on Investigational Drugs, 1999, 8, 777-785.	1.9	3
45	Anti-Tumor Immunity Elicited by a Recombinant Vaccinia Virus Expressing CD70 (CD27L). Human Gene Therapy, 1999, 10, 1095-1103.	1.4	62
46	Co-stimulatory molecules B7-1 and B7-2 as experimental therapeutic targets. Expert Opinion on Therapeutic Targets, 1999, 3, 93-108.	1.0	1
47	Combination Immunotherapy of B16 Melanoma Using Antiâ€"Cytotoxic T Lymphocyteâ€"Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation. Journal of Experimental Medicine, 1999, 190, 355-366.	4.2	951
48	Dysregulation of B7.2 (CD86) expression on monocytes of HIV-infected individuals is associated with altered production of IL-2. Clinical and Experimental Immunology, 1999, 117, 84-91.	1.1	33
49	Interaction Between B.7 and CD28 Costimulatory Molecules is Essential for the Activation of Effector Function Mediating Spontaneous Tumour Regression. Scandinavian Journal of Immunology, 1999, 49, 633-640.	1.3	9
50	Induction of abortive and productive proliferation in resting human T lymphocytes via CD3 and CD28. Immunology, 1999, 97, 280-286.	2.0	8
51	Alternative pathways for processing exogenous and endogenous antigens that can generate peptides for MHC class I-restricted presentation. Immunological Reviews, 1999, 172, 131-152.	2.8	95
52	Autologous lymphocyte responses to adenovirus-B7-1-transduced human cancer cells. Cancer Gene Therapy, 1999, 6, 195-208.	2.2	7
53	Adoptive-transfer therapy of tumors with the tumor-specific primary cytotoxic T cells induced in vitro with the B7.1-transduced MCA205 cell line. Cancer Immunology, Immunotherapy, 1999, 47, 257-264.	2.0	5
54	T cell mediated immunotherapy for B cell lymphoma. Journal of Molecular Medicine, 1999, 77, 322-331.	1.7	24

#	Article	IF	Citations
55	Growth of human fetal retinal pigment epithelium as microspheres. Graefe's Archive for Clinical and Experimental Ophthalmology, 1999, 237, 241-248.	1.0	12
56	Induction of effective antitumor immunity in a mouse brain tumor model using B7-1 (CD80) and intercellular adhesive molecule 1 (ICAM-1; CD54) transfection and recombinant interleukin 12. , 1999, 82, 714-720.		42
57	Expression of Costimulatory Molecules CD80 and/or CD86 by a Kaposi's Sarcoma Tumor Cell Line Induces Differential T-Cell Activation and Proliferation. Clinical Immunology, 1999, 91, 345-353.	1.4	17
58	ThÃ©rapie gÃ©nique en cancÃ©rologie : l'attente des rÃ©sultats cliniques. Annales De L'Institut Pasteur / ActualitÃ©s, 1999, 10, 313-325.	0.1	0
59	Gene Therapy in Oncology: Current Technical and Clinical Status of Development. Oncology Research and Treatment, 1999, 22, 11-16.	0.8	2
60	Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine. , 2000, 86, 725-730.		64
61	Differential requirement of perforin and IFN-Î³ in CD8 T cell-mediated immune responses against B16.F10 melanoma cells expressing a viral antigen. European Journal of Immunology, 2000, 30, 2507-2515.	1.6	45
62	Costimulatory wars: the tumor menace. Current Opinion in Immunology, 2000, 12, 589-596.	2.4	69
63	Local versus systemic interleukin-2: Tumor formation by wild-type and B7-1-positive murine melanoma cells. Cancer Gene Therapy, 2000, 7, 207-214.	2.2	9
64	Immunogene therapy against mouse leukemia using B7 molecules. Cancer Gene Therapy, 2000, 7, 144-150.	2.2	12
65	B7.1 expression by the weakly immunogenic F98 rat glioma does not enhance immunogenicity. Gene Therapy, 2000, 7, 993-999.	2.3	19
66	The role of CD40 in peripheral T cell tolerance and immunity. Journal of Molecular Medicine, 2000, 78, 363-371.	1.7	67
67	Antigenicity of human melanoma cells transfected to express the B7-1 co-stimulatory molecule (CD80) varies with the level of B7-1 expression. Cancer Immunology, Immunotherapy, 2000, 49, 85-93.	2.0	10
68	Significance and Regulation of the Expression of MHC Class II Molecules on Autoimmune and Neoplastic Thyroid Cells. , 2000, , 317-335.		1
69	Glioma Immunology and Immunotherapy. Neurosurgery, 2000, 46, 778-792.	0.6	118
70	CD27-Mediated Activation of Murine NK Cells. Journal of Immunology, 2000, 164, 1741-1745.	0.4	119
71	Clinical Protocol: A Phase I Trial of Intra Lesional RV-B7.1 Vaccine in the Treatment of Malignant Melanoma. Albert Einstein Center, Bronx, New York.. Human Gene Therapy, 2000, 11, 1065-1082.	1.4	18
72	Comparison of Cytokines and CD80 for Enhancement of Immunogenicity of Cervical Cancer Cells. Immunobiology, 2000, 202, 339-352.	0.8	7

#	Article	IF	Citations
73	Advances in specific immunotherapy of malignant melanoma. Journal of the American Academy of Dermatology, 2000, 43, 167-188.	0.6	43
74	Therapeutic Vaccination for Cancer. Clinical Immunology, 2000, 95, S44-S62.	1.4	62
75	B16 as a Mouse Model for Human Melanoma. Current Protocols in Immunology, 2000, 39, Unit 20.1.	3.6	298
76	Enhancement of natural killer cell-mediated cytotoxicity by coexpression of GM-CSF/B70 in hepatoma. Cancer Letters, 2001, 166, 33-40.	3.2	8
77	POTENT ANTITUMOR EFFECTS OF CD154 TRANSDUCED TUMOR CELLS IN EXPERIMENTAL BLADDER CANCER. Journal of Urology, 2001, 166, 1093-1097.	0.2	41
78	B7-H1 costimulation preferentially enhances CD28-independent T-helper cell function. Blood, 2001, 97, 1809-1816.	0.6	201
79	Dendritic cells and immunotherapy for malignant disease. British Journal of Haematology, 2001, 112, 874-887.	1.2	58
80	Decreased generation of anti-tumor immunity after intrasplenic immunization. European Journal of Immunology, 2001, 31, 1392-1399.	1.6	9
81	Peripheral Blood Dendritic Cells, but Not Monocyte-Derived Dendritic Cells, Can Augment Human NK Cell Function. Cellular Immunology, 2001, 213, 14-23.	1.4	28
82	B7.1 expression eliminates tumor resistance to IL-12 gene therapy. Cancer Gene Therapy, 2001, 8, 118-127.	2.2	8
83	Tricistronic viral vectors co-expressing interleukin-12 (1L-12) and CD80 (B7-1) for the immunotherapy of cancer: Preclinical studies in myeloma. Cancer Gene Therapy, 2001, 8, 361-370.	2.2	33
84	The immune anti-tumor effects of GM-CSF and B7-1 gene transfection are enhanced by surgical debulking of tumor. Cancer Gene Therapy, 2001, 8, 580-588.	2.2	38
85	Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature, 2001, 411, 1058-1064.	13.7	469
87	Large Nontransplanted Hepatocellular Carcinoma in Woodchucks: Treatment With Adenovirus-Mediated Delivery of Interleukin 12/B7.1 Genes. Journal of the National Cancer Institute, 2001, 93, 472-479.	3.0	61
88	B7H Costimulates Clonal Expansion of, and Cognate Destruction of Tumor Cells by, CD8+ T Lymphocytes In Vivo. Journal of Experimental Medicine, 2001, 194, 1339-1348.	4.2	111
89	Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 11515-11520.	3.3	299
90	Enhancement of Sindbis Virus Self-Replicating RNA Vaccine Potency by Targeting Antigen to Endosomal/Lysosomal Compartments. Human Gene Therapy, 2001, 12, 235-252.	1.4	72
91	Enhancement of Sindbis Virus Self-Replicating RNA Vaccine Potency by Linkage of Herpes Simplex Virus Type 1 VP22 Protein to Antigen. Journal of Virology, 2001, 75, 2368-2376.	1.5	80

#	Article	IF	Citations
92	Local Costimulation Reinvigorates Tumor-Specific Cytolytic T Lymphocytes for Experimental Therapy in Mice with Large Tumor Burdens. Journal of Immunology, 2001, 167, 3936-3943.	0.4	40
93	Inhibition of Murine Prostate Tumor Growth and Activation of Immunoregulatory Cells With Recombinant Canarypox Viruses. Journal of the National Cancer Institute, 2001, 93, 998-1007.	3.0	28
94	A Phase I Trial of Intralesional rV-Tricom Vaccine in the Treatment of Malignant Melanoma. Human Gene Therapy, 2001, 12, 1459-1480.	1.4	33
95	CD40 stimulation leads to effective therapy of CD40- tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 5561-5566.	3.3	210
96	A Role for IFN-Î³ in Primary and Secondary Immunity Generated by NK Cell-Sensitive Tumor-Expressing CD80 In Vivo. Journal of Immunology, 2002, 168, 4472-4479.	0.4	62
97	Improved Treatment of Pancreatic Cancer by IL-12 and B7.1 Costimulation: Antitumor Efficacy and Immunoregulation in a Nonimmunogenic Tumor Model. Molecular Therapy, 2002, 5, 405-412.	3.7	28
98	Failure of B7.1-modified tumor to evoke full activation of CD8+ tumor-infiltrating lymphocytes in the central nervous system: prevention of parental tumor growth in the subcutaneous environment. Journal of Neurosurgery, 2002, 97, 432-440.	0.9	2
99	Human Dendritic Cells Activate Resting Natural Killer (NK) Cells and Are Recognized via the NKp30 Receptor by Activated NK Cells. Journal of Experimental Medicine, 2002, 195, 343-351.	4.2	877
100	Negative effect of CTLA-4 on induction of T-cell immunity in vivo to B7-1+, but not B7-2+, murine myelogenous leukemia. Blood, 2002, 99, 2146-2153.	0.6	44
101	EBV Persistence in Vivo. , 2002, , 207-229.		0
102	Antitumor Immune Responses Derived from Transgenic Expression of CD40 Ligand in Myeloma Cells. Cancer Biotherapy and Radiopharmaceuticals, 2002, 17, 11-18.	0.7	12
103	Application of Candida solubilized cell wall Î²-glucan in antitumor immunotherapy against P815 mastocytoma in mice. International Immunopharmacology, 2002, 2, 59-67.	1.7	23
104	Noninfectious Gene Transfer and Expression Systems for Cancer Gene Therapy. , 2002, , 31-52.		9
105	Upregulation of natural killer cells functions underlies the efficacy of intratumorally injected dendritic cells engineered to produce interleukin-12. Experimental Hematology, 2002, 30, 195-204.	0.2	25
106	Cancer vaccines: dream, reality, or nightmare?. Clinical and Experimental Medicine, 2002, 2, 109-118.	1.9	8
107	The innate immune response to tumors and its role in the induction of T-cell immunity. Immunological Reviews, 2002, 188, 9-21.	2.8	194
108	Adenovirus-mediated gene transfer of B7.1 induces immunological anti-tumor effects in a murine brain tumor. Journal of Neuro-Oncology, 2002, 60, 13-23.	1.4	10
109	New Designs for Cancer Vaccine and Artificial Veto Cells: An Emerging Palette of Protein Paints. Immunologic Research, 2003, 27, 565-574.	1.3	12

#	Article	IF	Citations
110	Melphalan-induced up-regulation of B7â€“1 surface expression on normal splenic B cells. Cancer Immunology, Immunotherapy, 2003, 52, 162-170.	2.0	13
111	Enhancing CTL responses to melanoma cell vaccines in vivo : synergistic increases obtained using IFNÎ³ primed and IFNÎ² treated B7â€1 + B16â€F10 melanoma cells. Immunology and Cell Biology, 2003, 81, 459-471.	1.0	18
112	Induction of an antitumour adaptive immune response elicited by tumour cells expressing de novo B7-1 mainly depends on the anatomical site of their delivery: the dose applied regulates the expansion of the response. Immunology, 2003, 110, 474-481.	2.0	7
113	Immunotherapy and prostate cancer. Cancer Treatment Reviews, 2003, 29, 199-209.	3.4	34
114	Intra-Lesional rF-B7.1 Versus rF-TRICOM Vaccine in the Treatment of Metastatic Cancer. Human Gene Therapy, 2003, 14, 803-827.	1.4	12
115	Expression of costimulatory molecules in human neuroblastoma. Evidence that CD40+ neuroblastoma cells undergo apoptosis following interaction with CD40L. British Journal of Cancer, 2003, 88, 1527-1536.	2.9	31
116	Natural Killer Cells and Cancer. Advances in Cancer Research, 2003, 90, 127-156.	1.9	360
117	Suppression of peritoneal metastasis in human gastric carcinoma by enhanced immunogenicity of B7-1 transfection. Oncology Reports, 2004, 12, 53.	1.2	3
118	B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression. Clinical Cancer Research, 2004, 10, 5094-5100.	3.2	633
119	CD80 gene therapy for lymph node involvement by gastric carcinoma. International Journal of Oncology, 2004, 25, 1319.	1.4	1
120	Immunogenicity of Human Neuroblastoma. Annals of the New York Academy of Sciences, 2004, 1028, 69-80.	1.8	48
121	B7-2 expression above a threshold elicits anti-tumor immunity as effective as interleukin-12 and prolongs survival in murine B-cell lymphoma. International Journal of Cancer, 2004, 110, 61-69.	2.3	15
122	Identification of a Circulating Soluble Form of CD80: Levels in Patients with Hematological Malignancies. Leukemia and Lymphoma, 2004, 45, 2111-2118.	0.6	38
123	Usefulness of inhibiting the lymph node metastasis in human gastric carcinoma by B7â€“1 gene transfection1. Journal of Surgical Research, 2004, 122, 89-95.	0.8	11
124	Vaccine Therapy for Murine Glioma Using Tumor Cells Genetically Modified to Express B7.1. Neurosurgery, 2004, 54, 182-190.	0.6	9
125	Graft-versus-leukemia in a retrovirally induced murine CML model: mechanisms of T-cell killing. Blood, 2004, 103, 4353-4361.	0.6	37
126	Induction of T-Cell Apoptosis in Rats by Genetically Engineered Glioma Cells Expressing Granulocyte-Macrophage Colony-Stimulating Factor and B7.1. Clinical Cancer Research, 2005, 11, 1639-1649.	3.2	5
127	Genetically Engineered Myeloma Cell Vaccine. , 2005, 113, 235-244.		0

#	Article	IF	Citations
129	Liposomal vaccinesâ€"targeting the delivery of antigen. Methods, 2006, 40, 39-52.	1.9	80
130	Expression of Costimulatory Molecules on Human Retinoblastoma Cells Y-79: Functional Expression of CD40 and B7H1. , 2006, 47, 4607.		14
131	Induction of protective immunity to RM-1 prostate cancer cells with ALVAC-IL-2/IL-12/TNF-Î± combination therapy. International Journal of Cancer, 2006, 119, 2632-2641.	2.3	15
132	Enhanced Antitumor Effect of Oncolytic Adenovirus Expressing Interleukin-12 and B7-1 in an Immunocompetent Murine Model. Clinical Cancer Research, 2006, 12, 5859-5868.	3.2	115
133	The Role of Structurally Conserved Class I MHC in Tumor Rejection: Contribution of the Q8 Locus. Journal of Immunology, 2006, 177, 2123-2130.	0.4	8
134	Costimulation, Coinhibition and Cancer. Current Cancer Drug Targets, 2007, 7, 15-30.	0.8	86
135	General Principles of Tumor Immunotherapy. , 2007, , .		3
136	Expression of human leucocyte antigen G (HLA-G) is associated with prognosis in non-small cell lung cancer. Lung Cancer, 2007, 58, 267-274.	0.9	103
137	The combined actions of NK and T lymphocytes are necessary to reject an EGFP+ mesenchymal tumor through mechanisms dependent on NKG2D and IFNÎ³. International Journal of Cancer, 2007, 121, 1282-1295.	2.3	16
138	Robust anti-tumor immunity and memory in Rag-1-deficient mice following adoptive transfer of cytokine-primed splenocytes and tumor CD80 expression. Cancer Immunology, Immunotherapy, 2007, 56, 1955-1965.	2.0	4
139	Signaling through CD80: an approach for treating lymphomas. Expert Opinion on Therapeutic Targets, 2008, 12, 969-979.	1.5	28
140	Overcoming Immune Evasion in T Cell Therapy of Cancer: Lessons from Animal Models. Current Molecular Medicine, 2008, 8, 68-75.	0.6	10
141	CD40L-mediated inhibition of NF-kappaB in CA46 Burkitt lymphoma cells promotes apoptosis. Leukemia and Lymphoma, 2008, 49, 1792-1799.	0.6	5
142	A functional variant at miR-132-3p, miR-212-3p, and miR-361-5p binding site in CD80 gene alters susceptibility to gastric cancer in a Chinese Han population. Medical Oncology, 2014, 31, 60.	1.2	26
143	Concept of Reverse Costimulation and Its Role in Diseases. , 2015, , 45-81.		3
144	Costimulation in Lymphomas and Cancers. , 2015, , 185-254.		7
145	Mouse Model for Preâ€Clinical Study of Human Cancer Immunotherapy. Current Protocols in Immunology, 2015, 108, 20.1.1-20.1.43.	3.6	23
146	Regulation of NKG2D⁺CD8⁺T-cell-mediated antitumor immune surveillance: Identification of a novel CD28 activation-mediated, STAT3 phosphorylation-dependent mechanism. OncoImmunology, 2016, 5, e1252012.	2.1	21

#	Article	IF	Citations
147	Plasma membrane vesicles decorated with glycolipid-anchored antigens and adjuvants via protein transfer as an antigen delivery platform for inhibition of tumor growth. Biomaterials, 2016, 74, 231-244.	5.7	33
148	Evaluating the expression level of co-stimulatory molecules CD 80 and CD 86 in different types of colon polyps. Current Research in Translational Medicine, 2018, 66, 19-25.	1.2	6
149	Knockdown of LncRNA MALAT1 contributes to cell apoptosis via regulating NF-Î°B/CD80 axis in neonatal respiratory distress syndrome. International Journal of Biochemistry and Cell Biology, 2018, 104, 138-148.	1.2	17
150	SV-BR-1-GM, a Clinically Effective GM-CSF-Secreting Breast Cancer Cell Line, Expresses an Immune Signature and Directly Activates CD4+ T Lymphocytes. Frontiers in Immunology, 2018, 9, 776.	2.2	17
151	Rethinking peripheral T cell tolerance: checkpoints across a T cellâ€™s journey. Nature Reviews Immunology, 2021, 21, 257-267.	10.6	122
152	Triggering of Natural Killer Cell Mediated Cytotoxicity by Costimulatory Molecules. Current Topics in Microbiology and Immunology, 1998, 230, 53-61.	0.7	12
153	POTENT ANTITUMOR EFFECTS OF CD154 TRANSDUCED TUMOR CELLS IN EXPERIMENTAL BLADDER CANCER. Journal of Urology, 2001, , 1093-1097.	0.2	4
154	Identification of the site of Epstein-Barr virus persistence in vivo as a resting B cell. Journal of Virology, 1997, 71, 4882-4891.	1.5	282
155	The heat-stable antigen determines pathogenicity of self-reactive T cells in experimental autoimmune encephalomyelitis. Journal of Clinical Investigation, 2000, 105, 1227-1232.	3.9	64
156	Low Dose Decitabine Treatment Induces CD80 Expression in Cancer Cells and Stimulates Tumor Specific Cytotoxic T Lymphocyte Responses. PLoS ONE, 2013, 8, e62924.	1.1	92
157	<i>In situ</i>expression and significance of B7 costimulatory molecules within tissues of human gastric carcinoma. World Journal of Gastroenterology, 2003, 9, 1370.	1.4	24
158	Glioma Immunology and Immunotherapy. Neurosurgery, 2000, 46, 778-792.	0.6	89
159	Cancer-Specific Vaccines. , 2008, , 649-669.		1
160	Failure of Tumor Immunity Resulting from Inaccessibility of Activated Lymphocytes to Solid Tumors. , 1998, , 73-84.		0
161	Interleukin-12â€“Activated Natural Killer Cells Recognize B7 Costimulatory Molecules on Tumor Cells and Autologous Dendritic Cells. Blood, 1998, 91, 196-206.	0.6	11
162	Tumour immunology. , 1998, , 73-87.		1
163	SELF-NONSELF DISCRIMINATION OF ANTI-TUMOR IMMUNE RESPONSES. , 1998, , 123-143.		0
164	Vaccines using Gene-Modified Tumor Cells. , 1999, , 283-298.		0

#	Article	IF	Citations
165	Immunomodulatory Molecules of the Immune System. , 2007, , 67-121.		0
167	Induction of antigen-specific tumor immunity by genetic and cellular vaccines against MAGE: enhanced tumor protection by coexpression of granulocyte-macrophage colony-stimulating factor and B7-1. Molecular Medicine, 1996, 2, 545-55.	1.9	18
174	The Role of B7-1 and B7-2 Costimulation for the Generation of CTL Responses In Vivo. Journal of Immunology, 1998, 161, 2740-2745.	0.4	61
175	Host B7-1 and B7-2 Costimulatory Molecules Contribute to the Eradication of B7-1-Transfected P815 Tumor Cells Via a CD8+ T Cell-Dependent Mechanism. Journal of Immunology, 1999, 162, 4817-4823.	0.4	21
176	The Tumorigenicity of IL-2 Gene-Transfected Murine M-3D Melanoma Cells Is Determined by the Magnitude and Quality of the Host Defense Reaction: NK Cells Play a Major Role. Journal of Immunology, 1999, 162, 6650-6657.	0.4	14
177	Differential Coupling of Second Signals for Cytotoxicity and Proliferation in CD8+ T Cell Effectors: Amplification of the Lytic Potential by B7. Journal of Immunology, 1999, 163, 2999-3006.	0.4	29
178	NK Cell Triggering by the Human Costimulatory Molecules CD80 and CD86. Journal of Immunology, 1999, 163, 4207-4212.	0.4	80
179	VIP and PACAP Differentially Regulate the Costimulatory Activity of Resting and Activated Macrophages Through the Modulation of B7.1 and B7.2 Expression. Journal of Immunology, 1999, 163, 4213-4223.	0.4	55
180	Apoptosis of a Human Melanoma Cell Line Specifically Induced by Membrane-Bound Single-Chain Antibodies. Journal of Immunology, 1999, 163, 3948-3956.	0.4	9
181	Introduction on Immune Checkpoints in Cancer. , 2023, , 1-19.		0